NASDAQ:MRNA

Moderna (MRNA) Stock Forecast, Price & News

$100.27

+0.83 (+0.83%)

(As of 09/28/2023 ET)

Compare

Today's Range: $97.36
▼
$101.03
50-Day Range: $96.41
▼
$126.43
52-Week Range: $95.02
▼
$217.25

Volume: 2.03 million shs
Average Volume: 3.59 million shs
Market Capitalization: $38.16 billion

P/E Ratio: 37.00
Dividend Yield: N/A
Price Target: $155.52

Moderna MarketRank™ Forecast

Analyst Rating: Hold
2.17 Rating Score
Upside/Downside: 55.1% Upside
$155.52 Price Target
Short Interest: Bearish
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.71
Upright™ Environmental Score
News Sentiment: 0.59
Based on 13 Articles This Week
Insider Trading: Selling Shares
$23.61 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.32) to ($5.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

115th out of 970 stocks

Biological Products, Except Diagnostic Industry

12th out of 161 stocks

4.1

Analyst's Opinion

Consensus Rating
Moderna has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 6 buy ratings, 9 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $155.52, Moderna has a forecasted upside of 55.1% from its current price of $100.27.
Amount of Analyst Coverage
Moderna has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Moderna has been sold short.
Short Interest Ratio / Days to Cover
Moderna has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Moderna has recently increased by 0.61%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Moderna does not currently pay a dividend.
Dividend Growth
Moderna does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Moderna has received a 72.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "mRNA vaccines", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Moderna is -2.71.

2.5

News and Social Media Coverage

News Sentiment
Moderna has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Moderna this week, compared to 10 articles on an average week.
Search Interest
Only 57 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.
MarketBeat Follows
34 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 62% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,614,598.00 in company stock.
Percentage Held by Insiders
15.70% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.51% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Moderna are expected to decrease in the coming year, from ($4.32) to ($5.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Moderna is 37.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.13.
Price to Earnings Ratio vs. Sector
The P/E ratio of Moderna is 37.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.63.
Price to Book Value per Share Ratio
Moderna has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Moderna (NASDAQ:MRNA) Stock

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

MRNA Price History

30 days | 90 days | 365 days | Advanced Chart

MRNA Stock News Headlines

September 26, 2023 | reuters.com

EU in talks with Moderna over new deal for COVID vaccines - FT

September 26, 2023 | msn.com

Moderna in talks with EU over new COVID jab supply deal - Financial Times

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 26, 2023 | reuters.com

EU in talks with Moderna over new COVID vaccine deal - FT

September 24, 2023 | americanbankingnews.com

Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

September 23, 2023 | seekingalpha.com

Moderna: Now That The COVID Party Is Over, What's Next?

September 21, 2023 | seekingalpha.com

Moving Beyond COVID: A Conservative Options Income Strategy For Moderna

September 21, 2023 | msn.com

Moderna: Fortune Favors The Brave

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 21, 2023 | finance.yahoo.com

Does This Message From Moderna Mean Bad News for Novavax?

September 21, 2023 | americanbankingnews.com

Codiak BioSciences (NASDAQ:CDAK) and Moderna (NASDAQ:MRNA) Head to Head Analysis

September 20, 2023 | reuters.com

Pfizer forecasts 24% COVID vaccination rate in US this year

September 20, 2023 | americanbankingnews.com

Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of "Hold" by Brokerages

September 20, 2023 | msn.com

BRIEF-Moderna Ramps Down Mrna Drug Substance Production For Covid-19 Vaccine At Lonza, Switzerland

September 19, 2023 | msn.com

Moderna to Wind Down COVID Vaccine Production

September 19, 2023 | foxnews.com

Moderna to reduce COVID-19 vaccine production at Lonza's Swiss facility

September 19, 2023 | realmoney.thestreet.com

Moderna's Chart Messages Are Frustrating the Bulls

September 19, 2023 | reuters.com

Moderna to cut mRNA drug substance production at Lonza facility

September 19, 2023 | americanbankingnews.com

Insider Selling: Moderna, Inc. (NASDAQ:MRNA) President Sells 15,000 Shares of Stock

September 19, 2023 | americanbankingnews.com

Moderna (NASDAQ:MRNA) Stock Price Down 5.7% on Insider Selling

September 19, 2023 | msn.com

Pfizer and Moderna stocks tumble over anticipated low COVID-19 vaccination rate

September 18, 2023 | benzinga.com

Why Moderna Stock Is Sinking Today

September 18, 2023 | msn.com

Moderna (NASDAQ:MRNA)Plunges as COVID-19 Shot Market Collapses

September 18, 2023 | finance.yahoo.com

Moderna’s Stock Is S&P 500’s Biggest Loser Today

September 15, 2023 | benzinga.com

Moderna Unusual Options Activity For September 15

September 15, 2023 | msn.com

Moderna (NASDAQ:MRNA) Surges after Landing EU Approval

September 15, 2023 | washingtonpost.com

Moderna Faces Tougher Competition in Its Next Chapter

See More Headlines

Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

MRNA Company Calendar

Last Earnings: 8/03/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRNA
CUSIP: N/A
CIK: 1682852
Web: www.modernatx.com
Phone: (617) 714-6500
Fax: N/A
Employees: 3,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $155.52
High Stock Price Forecast: $296.00
Low Stock Price Forecast: $93.00
Forecasted Upside/Downside: +55.1%
Consensus Rating: Hold
Rating Score (0-4): 2.17
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.71
Trailing P/E Ratio: 37.00
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $8.36 billion
Net Margins: 11.33%
Pretax Margin: 7.68%
Return on Equity: 6.62%
Return on Assets: 4.93%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 3.39
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: $19.26 billion
Price / Sales: 1.98
Cash Flow: $23.26 per share
Price / Cash Flow: 4.31
Book Value: $49.78 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 380,590,000
Free Float: 320,840,000
Market Cap: $38.16 billion
Optionable: Optionable
Beta: 1.63

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Stephane Bancel (Age 50)
CEO & Director
Comp: $4.97M

Dr. Stephen Hoge M.D. (Age 47)
Pres
Comp: $2.41M

Mr. James M. Mock (Age 46)
Chief Financial Officer
Comp: $1.49M

Ms. Arpa Garay (Age 44)
Chief Commercial Officer
Comp: $2.67M

Dr. Jerh Collins Ph.D. (Age 57)
Chief Technical Operations & Quality Officer

Dr. Melissa J. Moore Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board

Mr. Brad Miller (Age 50)
Chief Information Officer

Ms. Lavina Talukdar CFA
Sr. VP & Head of Investor Relations

Ms. Shannon Thyme Klinger (Age 52)
Chief Legal Officer & Corp. Sec.

Colleen Hussey
Sr. Director of Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRNA Stock - Frequently Asked Questions

Should I buy or sell Moderna stock right now?: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.
What is Moderna's stock price forecast for 2023?: 18 brokers have issued 12-month target prices for Moderna's shares. Their MRNA share price forecasts range from $93.00 to $296.00. On average, they expect the company's share price to reach $155.52 in the next year. This suggests a possible upside of 55.1% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.
How have MRNA shares performed in 2023?: Moderna's stock was trading at $179.62 at the beginning of the year. Since then, MRNA stock has decreased by 44.2% and is now trading at $100.27.
View the best growth stocks for 2023 here.
When is Moderna's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRNA earnings forecast.
How were Moderna's earnings last quarter?: Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.84) by $0.22. The firm earned $344 million during the quarter, compared to the consensus estimate of $307.67 million. Moderna had a net margin of 11.33% and a trailing twelve-month return on equity of 6.62%. The firm's quarterly revenue was down 92.8% on a year-over-year basis. During the same period in the previous year, the firm earned $5.24 earnings per share.
What ETFs hold Moderna's stock?: ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), iShares Genomics Immunology and Healthcare ETF (IDNA), ProShares Nanotechnology ETF (TINY) and iShares U.S. Tech Breakthrough Multisector ETF (TECB).
What is Stéphane Bancel's approval rating as Moderna's CEO?: 57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).
When did Moderna IPO?: (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.
What is Moderna's stock symbol?: Moderna trades on the NASDAQ under the ticker symbol "MRNA."
How do I buy shares of Moderna?: Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Moderna's stock price today?: One share of MRNA stock can currently be purchased for approximately $100.27.
How much money does Moderna make?: Moderna (NASDAQ:MRNA) has a market capitalization of $38.16 billion and generates $19.26 billion in revenue each year. The company earns $8.36 billion in net income (profit) each year or $2.71 on an earnings per share basis.
How many employees does Moderna have?: The company employs 3,900 workers across the globe.
How can I contact Moderna?: Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.

This page (NASDAQ:MRNA) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial